Market capitalization | $6.28m |
Enterprise Value | $-230.00k |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.02 |
P/B ratio (TTM) P/B ratio | 3.00 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-13.77m |
Free Cash Flow (TTM) Free Cash Flow | $-12.48m |
Cash position | $6.51m |
As a Free StocksGuide user, you can view scores for all 6,892 stocks worldwide.
1 Analyst has issued a forecast GT Biopharma Inc:
1 Analyst has issued a forecast GT Biopharma Inc:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | -14 -14 |
15%
15%
|
EBIT (Operating Income) EBIT | -14 -14 |
15%
15%
|
Net Profit | -12 -12 |
21%
21%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based proprietary TriKE NK cell engager platform. The TriKE platform is designed to harness and enhance the cancer killing abilities of a patient's immune system natural killer cells (NK cells). Its product GTB-3550 is initially developed for the treatment of AML and MDS, and other CD33+ hematologic cancers. GT Biopharma has worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology. The company was founded in 1965 and is headquartered in Beverly Hills, CA.
Head office | United States |
CEO | Michael Breen |
Employees | 2 |
Founded | 1965 |
Website | www.gtbiopharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.